Atossa Therapeutics
ATOS
23 hedge funds and large institutions have $1.79M invested in Atossa Therapeutics in 2020 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 1 closing their positions.
2,027% more capital inflows, than outflows
Capital inflows: $1.43M | Capital outflows: $67.4K
1,100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 1
91% more call options, than puts
Call options by funds: $63K | Put options by funds: $33K
77% more funds holding
Funds holding: 13 → 23 (+10)
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
3.72% more ownership
Funds ownership: 3.38% → 7.1% (+3.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$421K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$282K |
| 3 |
Renaissance Technologies
New York
|
+$238K |
| 4 |
Two Sigma Investments
New York
|
+$134K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$78.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$65K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.49K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$624 |
| 4 |
CG
Cutler Group
San Francisco,
California
|
-$336 |
ATOS Hedge Fund Activity: Q3 2020 in Review
23 of the 4,972 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q3 2020, worth a combined $1.79M — up 51% from $1.18M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ATOS positions and 1 closed out — a net gain of 11 holders — while 4 added to existing stakes and 3 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $421K. The largest seller was Susquehanna International Group, cutting an estimated $65K.
- 23 institutional investors held Atossa Therapeutics (ATOS) as of Q3 2020, up from 13 in Q2 2020.
- Funds reported $1.79M of Atossa Therapeutics stock for Q3 2020, up 51% quarter-over-quarter.
- 12 funds opened new Atossa Therapeutics positions in Q3 2020 and 1 closed out, a net change of +11 holders.
- The largest Atossa Therapeutics buyer in Q3 2020 was Morgan Stanley, an estimated $421K added.
- The largest Atossa Therapeutics seller in Q3 2020 was Susquehanna International Group, an estimated $65K sold.
Based on aggregated 13F filings for Q3 2020.